Trial | NCT00006591  Report issue

Title

Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    None
The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.
HIV-infected patients will be treated with a ritonavir-enhanced Agenerase regimen.
Study Started
Dec 01
2000
Last Update
Jun 24
2005
Estimate

Drug Ritonavir

Drug Amprenavir

Criteria 

Inclusion Criteria

Patients may be eligible for this study if they:

Are 18 years of age or older.
Are HIV-positive.
Have a viral load (level of HIV in the body) of more than 1,000 copies/ml.
Have had more than 12 weeks of prior anti-HIV drug treatment.
Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor.
Are responsive to Agenerase.
Are able to follow study requirements.

Exclusion Criteria

Patients will not be eligible for this study if they:

Are intolerant to ritonavir (an anti-HIV drug).
Have or have had problems with absorption.
Have liver disease or damage.
Have pancreatic disease or damage.
Have taken any protease inhibitor other than nelfinavir.
Are receiving investigational drugs or devices from another study.
Are pregnant or breast-feeding.
Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide.
Have a bleeding disorder.
Have previously been treated with Agenerase.
Are receiving nonnucleosides.
No Results Posted